Home / Market News / $CLDX
fiscal.ai Corporate Catalyst Impact 65/100 ● positive

Morgan Stanley Maintains Celldex Therapeutics at Overweight, Raises Price Target to $61

Nov 9, 2026, 7:12 PM UTC · Primary ticker $CLDX

Morgan Stanley has reiterated its 'Overweight' rating for Celldex Therapeutics and increased its price target to $61 from $57. This upgrade suggests a significant potential upside of 104.2% from the stock's closing price on November 6, 2026, indicating a positive outlook from the analyst firm.

Morgan Stanley has reaffirmed its 'Overweight' rating on Celldex Therapeutics and raised its price target from $57 to $61. This 7.0% increase in the price target implies a substantial 104.2% upside from the stock's November 6, 2026 closing price of $29.87. This analyst upgrade is a positive signal for investors, suggesting increased confidence in the company's future performance and potential for significant stock appreciation. For traders, this could lead to short-term buying interest as the market reacts to the revised target, while long-term investors might view this as validation of their holdings. The key opportunity for traders lies in capitalizing on the immediate positive sentiment and potential price movement following the announcement.

$CLDX positive Analyst price target increase
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.